ArticleTranslational cancer research2026
The construction and validation of a nomogram for lung metastasis of intrahepatic cholangiocarcinoma: a study based on the SEER database.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung metastasis is the most common extrahepatic metastasis organ for intrahepatic cholangiocarcinoma (ICC), often leading to an unfavorable prognosis. Although nomograms exist for predicting the risk of distant metastasis in ICC patients, a precise prognostic model specifically for patients with established intrahepatic cholangiocarcinoma lung metastasis (ICCLM) remains lacking. The aim of this study was to develop and validate a prognostic nomogram for predicting cancer-specific survival (CSS) in patients with ICCLM based on the Surveillance, Epidemiology, and End Results (SEER) database. Methods: We extracted data on 620 patients with ICCLM from the SEER database spanning the years 2010 to 2020. Patients from 2010 to 2017 were randomly allocated to a training cohort (n=274) and an internal validation cohort (n=118). Data from 2018 to 2020 (n=228) served as the external validation cohort. Employing both univariate and multivariate Cox regression analyses, we identified independent prognostic factors for ICCLM and subsequently developed a nomogram for CSS prediction. The performance of the nomogram was then assessed using the C-index, calibration plot, receiver operating characteristic (ROC) curve, and decision curve analysis (DCA). Kaplan-Meier (KM) survival curves were plotted to illustrate survival disparities across different risk strata. Results: Based on these factors, a nomogram was constructed. In the training, internal validation, and external validation cohorts, the C-index of the nomogram was 0.723, 0.761, and 0.758, respectively. The calibration curve, ROC curve, and DCA demonstrated commendable performance in predicting the 3-, 6-, and 12-month CSS for ICCLM patients. The KM survival analysis indicated that the 1-, 3-, and 5-year CSS rates for ICCLM patients were 23.9%, 3.3%, and 0.8%, respectively, with a median CSS of 5 months. Notably, there was a significant survival disparity between the low- and high-risk groups (P<0.05). Conclusions: The constructed nomogram stands out as a potent, individualized prognostic tool for ICCLM patients, poised to guide clinicians in tailoring more strategic and efficacious therapeutic regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.